… to be related to use of evolocumab. However, other top reported reasons for evolocumab
therapy discontinuation, including reimbursement, patient request, and administrative decision, …

Introduction This study characterizes patients receiving evolocumab in clinical practice and
assesses treatment effectiveness, safety and persistence outcomes across five countries. …

… evolocumab was maintained in the longer term, and it was well tolerated. In conclusion,
subcutaneous evolocumab is a valuable new treatment for use … , particularly in patients unable to …

… have demonstrated lipid-lowering efficacy across a broad patient population. In this
section, we highlight the effects of evolocumab in patients with and without familial …

… evolocumab in a pre-specified analysis of patients by LDL receptor mutation status. In patients
… in both alleles (of which at least one was defective), evolocumab reduced LDL-C by 41%. …

… the effectiveness of evolocumab in the management of hyperlipidemia. Evolocumab seems
to … Hence, it provides an excellent alternative for patients with refractory disease or patients …

… disease risks, and baseline use of lipid-lowering therapy. A … 1104 patients from the phase
2 trials compared evolocumab … evolocumab with placebo in patients with hyperlipidemia who …

… (May 8 issue)2 on the durable effects of evolocumab in … were reported in four patients receiving
evolocumab (including two … occurred during treatment with evolocumab (no strokes were …

… of 12 Phase II or III evolocumab trials were eligible to … patients were randomized 2:1 to
receive evolocumab plus standard therapy or standard therapy alone. At week 12, evolocumab …

… This analysis evaluated the effects of evolocumab in participants with mixed hyperlipidemia
(hypercholesterolemia with triglycerides ≥1.7 mmol/L [150 mg/dL]) and participants with …